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Introduction
Biomedical research is critical to identifying eﬀ  ective and 
safe interventions, such as vaccines, microbicides, male 
circumcision and antiretrovirals, for HIV prevention. It is 
also a resource-intensive endeavour in terms of funding, 
clinical infrastructure, oversight and scientiﬁ  c capacity. 
Th   e nature of the HIV epidemic is such that prevention 
research is situated with poverty, exploitation, assaults on 
human dignity, and human rights abuses. Th   e result is a 
complex web of research and intervention challenges that 
are socially constructed along lines of wealth and power. 
A wide range of disciplines, collectively known as the 
social sciences, have long made such phenomena an 
object of study and discourse: anthropology, sociology, 
political science, history, economics and geography, to 
name a few. Yet despite the fact that social science research 
methods are commonly employed to examine such 
topics, they have played a marginal role in biomedical 
HIV prevention research.
What follows is a retrospective based on my personal 
experiences as a social scientist actively collaborating 
with biomedical HIV prevention researchers conducting 
vaccine, microbicide and pre-exposure prophylaxis (PrEP) 
trials. Beginning in the early 1990s, I was one of many US 
government scientists tasked with planning for the ﬁ  rst 
HIV vaccine trials. Th  ose leading the eﬀ  ort recognized 
the need to address a wide range of social and behavioural 
questions [1]. Would AIDS stigma deter people from 
participating? Could we eﬀ   ectively recruit and screen 
trial participants when this required asking them about 
stigmatized sexual and drug-using behaviours? Could we 
successfully enrol and retain people who were at high risk 
for HIV, but who were also marginalized in their own 
communities? Could we prevent people in a vaccine trial 
from believing that they were protected and taking risks 
they otherwise would not? How could biomedical HIV 
prevention researchers overcome the distrust of science 
and government-funded research that grew out of an 
unfortunate and recurring history of medical exploitation 
of the vulnerable?
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ﬁ  elded in various US cities in 1993, the lead investigators 
reﬂ  ected the multidisciplinary nature of the questions to 
be addressed: epidemiology, medicine, psychology, 
sociology, anthropology, public health and social work. 
Th  is was despite the fact that overall leadership for the 
work was housed in the solidly biomedical National 
Institute of Allergy and Infectious Diseases at the 
National Institutes of Health (NIH).
Th  e approach was, in retrospect, a groundbreaking 
endeavour. To be sure, the ground was, and remains, 
rocky and tangled with deeply established roots. In my 
experience, the social sciences have had the greatest 
diﬃ   culty establishing themselves in this terrain. Yet the 
social dimensions are among the most critical for 
success  ful prevention trial implementation and transla-
tion of trial ﬁ  ndings to eﬀ  ective prevention programmes. 
Th   rough this retrospective, I hope to throw some light on 
the obstacles, the successes and the opportunities for 
social scientists in this challenging ﬁ  eld.
Biomedical HIV prevention: a brief overview
Because HIV is a global epidemic, eﬀ  orts similar to the 
early US preparatory studies emerged elsewhere. Th  e 
World Health Organization (WHO) (and later UNAIDS) 
and NIH independently established international pro-
grammes to build capacity for HIV vaccine trials in 
Africa, Asia and Latin America. European nations, 
Australia and Canada similarly developed national and 
international research agendas. Scientiﬁ   c centres with 
strong in-country leadership emerged in Th  ailand,  Brazil, 
South Africa and elsewhere [1-3]. Th  e biomedical HIV 
prevention research agenda diversiﬁ  ed to include micro-
bicides, interventions to prevent mother to child trans-
mission, medical male circumcision, treatment of 
sexually transmitted infections that facilitated HIV trans-
mission, PrEP, and early antiretroviral treatment of HIV 
infection to reduce transmission by reducing viral load. 
Complex partnerships with pharmaceutical companies 
were developed, scientiﬁ  c non-proﬁ  ts formed with the 
goal of accelerating the development of vaccines and 
microbicides, and advocacy groups emerged to promote, 
support and build awareness for biomedical HIV 
prevention.
Th  e large-scale phase III HIV vaccine eﬀ  ectiveness 
trials that were the impetus for the early US preparedness 
studies were not implemented. In a controversial and 
hotly debated decision-making process in 1995, NIH 
concluded that the results from smaller phase II trials did 
not support further testing. As Cohen describes in detail 
in a chapter titled “Perpetual Uncertainty” is his 2001 
book on the search for an AIDS vaccine, the decision 
reﬂ  ected concerns about community readiness, as well as 
scientiﬁ  c uncertainties [4].
As the years unfolded, it became clear that controversy 
would be the norm for biomedical HIV prevention. Since 
the mid-1990s, dozens of biomedical HIV prevention 
trials have been implemented, most with ﬂ  at or negative 
results [5]. Th   ere have been highly charged debates about 
the plausibility, utility, ethics, viability and acceptability 
of every biomedical intervention tested in phase II and III 
trials [4,6]. Despite these challenges, by mid-2011, we 
had evidence that oral PrEP and antiretroviral-based 
vaginal gels were partially protective for at least some 
populations when used consistently, that a two-vaccine 
combination may be marginally protective, that medical 
circumcision reduced infection rates in men by 60%, that 
early antiretroviral treatment could reduce transmission 
by reducing viral load, and that the proper use of 
antiretrovirals could virtually eliminate mother to child 
HV transmission in the absence of breastfeeding [7-14]. 
Despite all the controversies, ﬂ   at results and failures, 
biomedical options clearly are an important and growing 
part of the HIV prevention toolkit.
Discussion
Interlocking challenges
Most biomedical HIV prevention research is funded 
publicly or through non-proﬁ  t foundations, yet the fund-
ing context is highly competitive and the benchmarks of 
success ultimately reduce to the same three that drive 
proﬁ  t-driven research: quickly enrolling a select group of 
people at risk, keeping them enrolled, and inducing them 
to be compliant with trial requirements – all at the lowest 
cost possible. As noted previously, this reality is situated 
within a complex web of persistent interlocking social, 
behavioural and ethical challenges.
To a large extent, stigma sits at the core of the interlock. 
In his seminal sociological work, Goﬀ  man  identiﬁ  ed 
three categories of stigma: physiological, including 
disease; behavioural; and social [15]. HIV sits at the 
intersection of all three: it is a deadly and debilitating 
disease; it is transmitted via behaviours subject to moral 
judgment, including sex and drug use; and in non-
generalized epidemics, it is often most prevalent among 
groups subject to multiple forms of discrimination and 
marginalization. Stigma serves to perpetuate the HIV 
epidemic by creating barriers to prevention and treat-
ment and compounding the struggles of individuals, 
families and communities aﬀ  ected [16,17].
Distrust of medical research, government agencies and 
international entities is another core component of the 
interlock. Th   e uncontested examples of exploitation and 
harm are too numerous to cite here, ranging from Nazi 
experimentation on concentration camp prisoners in the 
World War II era to the Tuskegee syphilis study among 
impoverished African Americans in the post-war era to 
the post-2000 Discovery Laboratories’ proposal to 
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treatment for Respiratory Distress Syndrome in infants in 
Latin America despite the existence of approved treat-
ment drugs in the US [18,19].
Th   e scientists involved in these and other exploitative 
studies typically cited contributions to a greater good as 
justiﬁ  cation. In some cases, arguments were made that 
no real harm was done because the research subjects 
were lacking access to adequate care anyway, were given 
other beneﬁ   ts (e.g., coverage of burial costs in the 
Tuskegee study), or were going to die regardless of 
partici  pation in research. More politely put, many of the 
researchers did not actively increase the level of harm 
experienced by participants, but neither did they use the 
opportunity to mitigate harm with the resources and 
knowledge at hand via the research.
Most of the major controversies surrounding HIV 
prevention trials reference this history because the trials 
are situated on the jagged divide between those with 
wealth and power and those without [20,21]. Perhaps 
unique to the HIV context, the controversies ultimately 
brought researchers and advocates together to ﬁ  nd ways 
to bridge the divide. Th  e result has been open dialogue 
about the most challenging ethical dilemmas, stronger 
partnerships between civil society and research, and 
innovative solutions to improving healthcare access for 
participants in HIV prevention trials [22,23].
Framing the social
Ultimately the persistent interlocking social, behavioural 
and ethical challenges are about social relationships. Yet 
they have been framed primarily in behavioural and 
ethical terms. Th  e result is an oversimpliﬁ  cation of the 
social processes at work and reliance on a limited set of 
social science methods to explore and inform decision 
making. Examples of how this framing has devalued 
social knowledge include the conﬂ   ation of qualitative 
research with anecdotal reporting, the privileging of 
brevity and accuracy over external validity, and diﬃ   cul-
ties in distinguishing between a moral understanding of 
social norms and achieving a moral outcome when 
confronted with ethical challenges in research.
Social scientists are now integrated as members of 
biomedical HIV prevention trial research teams, yet 
social science is minimally integrated with the science of 
biomedical HIV prevention. Th   is is seen most notably in 
a trend toward funding biomedical researchers to lead 
increasingly complex intervention designs that include 
social interventions (with an emphasis on community, 
peer and household relationships). However, the trials 
rarely engage in in-depth, reﬂ  exive social science research 
on the broader implications of interventions for the 
communities and health systems within which they may 
be delivered.
Confl  ation of qualitative research and anecdotal reports
Th   ere are two misconceptions about qualitative research 
that create barriers to the development of a systematic 
social science research agenda related to biomedical HIV 
prevention. First is a prevalent assumption that quali-
tative research is quick, cheap and simple to conduct. 
Unfortunately, social scientists can be their own worst 
enemies on this issue.
For example, some ethnographers describe their 
approach as “deep hanging out”, following a popular 
article title by noted anthropologist Cliﬀ  ord Geertz [24]. 
Th  ose trained in ethnographic research understand the 
nuances embedded in that phrase and realize that it is an 
attempt to explain a complex method by reference to a 
superﬁ  cially similar social activity: it looks like loitering 
to the untrained eye, but is actually work. To people who 
spend long days in clinics and laboratories trying to 
ﬁ   gure out why one person is infected with HIV and 
another is not, the nuance of “deep hanging out” is lost. It 
sounds either like self-serving rationalization or some-
thing simple that a motivated clinician could do in her 
spare time. She can hang out in the waiting room or the 
local market, talking to people and hearing their stories. 
She can invite community members and study partici-
pants to a small group meeting, call it a focus group, and 
see what they think about the research being done out of 
the clinic.
Medical practitioners and researchers write and submit 
anecdotal reports to their journals all the time, and have 
developed standardized guidance and formats for pre  sent-
ing case examples [25]. Patient case reports are considered 
“valuable resources of new and unusual infor  ma  tion that 
may lead to vital research”, but are not con  sidered to be 
research ﬁ   ndings themselves [26]. Th   e “unique and 
illustrative example” is well received and makes for 
interest ing  presentations.
Th  ese are not the same as doing a well-designed 
qualitative study that explicitly addresses issues of subjec-
tive bias and perspective. Biomedical researchers under-
stand the potential for bias in anecdotal reports, but have 
developed a narrow approach for how to address it [26]. 
As social scientists, we need to do a better job of framing 
what we do relative to the standards of bio  medicine if we 
want our ﬁ  ndings to be given the weight they deserve.
Th  e conﬂ  ation of qualitative research with anecdotal 
reports and informal observation is also seen in confu-
sion about the distinction between doing social science 
research on the one hand and, on the other, using the 
good participatory practices in biomedical research out-
lined in the guidance developed by AVAC and UNAIDS 
[23]. Th  is is a fuzzy area because good participatory 
practices are often informed by social science research, 
and social science research is often conducted using par-
tici  patory principles. Th   ere is thus a natural relationship 
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biomedical research. But there is also an important 
diﬀ  erence that is ignored to the detriment of both.
Presenting evidence of the how and why of stigma, 
documenting its impact on life choices and health 
incomes, and developing case examples of the way gender 
dynamics compound the eﬀ  ects of stigma on households 
are examples of research that can inform advocacy for 
research participants, guidelines for trial implementation 
and the roll out of comprehensive biomedical inter  ven-
tions. But it entails more than telling a powerful story 
about a person’s life. Social science research seeks to 
contextualize the story within competing social agendas, 
to relate it to other stories and to understand if it is 
typical or exceptional. Advocacy seeks to contextualize 
the story within an admittedly biased perspective and 
with a stated end goal in mind. Advocacy entails the 
selective use of information. Th   ere is an inherent problem 
with conﬂ  ating this advocacy end goal with the means of 
social science research.
I am not arguing that social scientists should not 
engage in advocacy or that they should discourage the 
use of their ﬁ  ndings for advocacy. HIV researchers in 
general are among some of the most eﬀ  ective  and 
powerful advocates for the people and communities 
impacted by the disease and its drivers. But social science 
warrants a platform and recognition as science. A review 
of the scientiﬁ  c programme for almost any major HIV 
conference in the past 20 years is likely to show that 
social science contributions are either absent or rolled 
together with advocacy. Th  e result is a social science 
standard limited to reportage and commentary, with few 
structured opportunities to generate a synthesis of 
cumulative ﬁ  ndings that point with some clarity toward 
next steps. Th  is is in stark contrast to the standard for 
clinical, laboratory and behavioural HIV research.
Privileging of brevity and accuracy over external validity
When social science is not being lumped with advocacy, 
it is often redeﬁ  ned as a sub-discipline of behavioural 
science. Again, there is a natural relationship between the 
two and important work that straddles them, but they are 
not the same. Social science pursues knowledge about 
people in relationship to each other; behavioural science 
pursues understanding of people as individuals. When a 
behavioural scientist considers social context, it is to 
understand how it inﬂ  uences an individual’s behaviour. 
When a social scientist considers behaviour, it is to 
under  stand how it simultaneously emerges from and 
inﬂ   uences the dynamics of human relationships at 
multiple levels. Context is a predictor or a modiﬁ  er for 
behavioural scientists, and a dynamic set of interlocking 
systems for social scientists. Th   ey are diﬀ  erent 
paradigms.
A social science perspective on biomedical inter  ven-
tions brings to the fore important questions about how 
such interventions function as components of systems. 
Clinical HIV prevention trials are peculiar endeavours in 
that they attempt to maximize the generalizability of the 
biomedical ﬁ  ndings concerning eﬃ   cacy or eﬀ  ectiveness 
by controlling for the inﬂ   uence of environment and 
behaviour (including the behaviour of the research team, 
as well as that of the participant). Generalizability of the 
process by which the intervention is implemented has 
been dismissed as infeasible due to the fact that clinical 
trials are very diﬀ   erent contexts from the real-world 
context within which successful biomedical interventions 
will need to be deployed. Th   is dismissal misses the point 
of external validity, which includes the opportunity to 
assess the gradient of similarity between the clinical 
research and the programme implementation contexts to 
identify the degree of generalizability.
For example, many research teams have developed ad 
hoc procedures to improve microbicide adherence in the 
context of gender power dynamics in a range of cultural 
contexts. A social analysis across multiple trials could 
describe the potential generalizability of such procedures 
to the programme implementation context. Additionally, 
it could point toward development of combination 
preven  tion strategies that include structural components 
to address gender-based drivers of risk together with 
biomedical components to reduce biological vulnera-
bilities [27]. Latkin and colleagues oﬀ  er a comprehensive 
framework for considering how to describe the inter-
connected and dynamic processes of change across multiple 
levels in dynamic social systems, which could provide a 
helpful starting place for this kind of analysis [28].
Lumping social science with behavioural science fosters 
a reduction of research questions to the level of the 
individual. Structural constraints within the clinical trials 
research context then further limits the scope of the 
research. Trial funding is generally tight and the research 
team is under pressure to begin enrolling participants as 
soon as possible. In an eﬀ   ort to minimize costs and 
implementation delays, data collection instruments are 
often limited in content, unsophisticated in design, and 
rarely piloted and validated prior to being implemented. 
Simultaneously, there is a presumption that the primary 
limiting factor for the utility of the data is the numeric 
accuracy of self-reported information. Th  e result has 
been duplicative documentation of a narrow set of 
behavioural issues related to behavioural risk, accept-
ability, adherence, comprehension and getting study 
participants to answer questions truthfully and accurately. 
Th  e data are used primarily to ﬁ  x trial implementation 
problems on the ﬂ  y, to demonstrate that problems were 
resolved, or to address political challenges for the clinical 
investigator.
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because they are primarily deﬁ  ned as practical clinical 
research questions, there are barriers to using the ﬁ  nd-
ings as a foundation for deepening our understanding of 
either the behavioural or social dimensions of biomedical 
prevention. Worse, the resultant ﬁ  ndings are minimally 
informative for interpreting trial outcomes. Th  e  perverse 
outcome of this devaluing of standards is a questioning of 
the value of both social and behavioural science for 
biomedical prevention.
Despite the barriers, there are encouraging examples of 
a more nuanced approach, particularly in the ﬁ  eld  of 
microbicides with its strong history of community 
advocacy and linkages to women’s health and gender 
equity [29]. Th  e MDP301 Pro2000 microbicide trial 
included a range of quantitative and qualitative data 
collec  tion strategies with participants and their partners 
that supported extensive use of triangulation [30,31]. Th  e 
Carraguard microbicide research programme included 
assessment of social issues in earlier stage trials with 
incorporation of ﬁ  ndings into later trial design [32]. Th  e 
recently closed FEM-PrEP oral PrEP trial included a 
comprehensive social and behavioural research compo-
nent with community mapping, quantitative and qualita-
tive data collection with participants and stakeholders, 
and use of social marketing methods to inform planning 
for potential roll out if the intervention proved successful 
[33-36].
Distinguishing moral understanding and moral 
outcomes
Many of the social issues surrounding biomedical HIV 
prevention trials are framed as primarily ethical issues or 
challenges. Th  is has resulted in a greater valuing of 
philosophical and logical argumentation over observation 
and evaluation for understanding and addressing the 
social dimensions of ethical challenges. Contextual under-
standing of the lives of people and the values they share – 
understanding why values diﬀ   er from one context to 
another and the extent to which competing values may 
exist in a given setting – has at times been re-labelled as 
ethical relativism and condemned as supportive of 
exploitation, discrimination and human rights abuses. 
Or, it has been expropriated, for example, by facile 
arguments that interpret greater respect for local culture 
as “ethical” justiﬁ  cation for requiring women to obtain 
their husbands’ consent to participate in research. 
Uninformed by a more nuanced social analysis, such 
arguments have promoted a disregard for women’s 
autonomy in some quarters.
In contrast, through analysis of the discourse around 
this issue by a wide range of stakeholders in diverse 
research communities, social science research on the 
underlying gender power dynamics has highlighted a 
space where respectful engagement can be negotiated 
without requiring complacency in the face of inequity 
and discrimination, and certainly without excusing the 
willful exploitation of inequities between well-resourced 
researchers and poorly resourced communities [27,37,38]. 
As Macklin notes, “It is one thing to provide an 
explanation of why an individual or entire culture holds 
certain beliefs and acts in certain ways. It is quite another 
thing to provide a justiﬁ   cation for those beliefs and 
actions” [6; see page 24]. I would add that it is yet another 
thing to create a path from one set of established beliefs 
and norms about what is right to an alternative set in the 
limited context of biomedical research. Understanding 
local moral systems is an essential component to any 
eﬀ  ort seeking to achieve moral outcomes deﬁ  ned at a 
level of global discourse.
Beyond the context of HIV prevention clinical trials, 
social scientists have been signiﬁ  cant contributors to the 
growing ﬁ  eld of empirical and applied research ethics. 
For example, the journal, Social Science and Medicine, 
published a special issue on social science and bioethics 
in the African context [39]. Speciﬁ  c to HIV prevention 
trials, we can cite empirical research on informed 
consent, community engagement and ancillary care that 
has informed the conduct of clinical trials [38,40-43]. 
Nonetheless, there have been few social analyses of the 
results of eﬀ  orts to implement ethics guidance for HIV 
prevention trials.
Here again, there has been a general lack of consoli-
dation and synthesis and a tendency toward replicating 
the same basic research with each prevention modality 
and even each trial. Since many of the ethical challenges 
confronting HIV prevention trials grow out of the social 
conditions within which the epidemic is embedded, a 
synthesis of applied ethics experience and ﬁ  ndings from 
the trials could do much to inform the ethical challenges 
that will confront the development and scale up of 
combination prevention approaches.
Social science research opportunities
For the past 20 years, it was arguably premature to devote 
limited resources to hypothetical social challenges 
speciﬁ   c to the roll out of yet-unproven interventions, 
such as vaccines, microbicides and PrEP. Th   at said, many 
of the hypothetical challenges were in fact already in play, 
beginning with eﬀ  orts to roll out condoms (male and 
female) and to facilitate access to sterile injecting 
equipment for drug users. We may have lost important 
opportunities to eﬃ   ciently explore means for addressing 
challenges that cross-cut multiple HIV prevention 
modalities by viewing clinical prevention trials as outside 
the realm of public health practice.
Biomedical prevention research is now in a transition 
from a preponderance of trials with ﬂ   at or negative 
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eﬀ   ectiveness for speciﬁ   c populations and modes of 
transmission. With the transition, there is now clear 
beneﬁ   t to enhancing the success of biomedical HIV 
prevention research through development of a coherent 
programme of social science research that can address 
known and likely challenges to programmatic success.
Achieving moral outcomes
An important emerging challenge related to partial 
eﬀ  ectiveness centres on determining ethical standards of 
prevention care for future HIV prevention trial partici-
pants [44]. Since the early 1990s, appropriate prevention 
standards have been debated in terms of the potential for 
exploitation of participant vulnerability and risk, 
practical implications for eﬃ     cient clinical trial design, 
sensitivity to local context (including regulations about 
provision of injecting equipment for drug users), whether 
access to otherwise unavailable prevention services could 
constitute undue inducement for trial participation, and 
sustainability of the services in the community after the 
trial. A consensus minimal standard emerged that 
included client-centred HIV risk reduction counselling, 
screening for and treatment of curable sexually 
transmitted infec  tions, and provision of male and female 
condoms.
Updated ethical guidance from UNAIDS and WHO in 
2007 cited a higher standard that includes “all state-of-
the-art risk reduction methods”, yet then qualiﬁ  es this 
requirement by stating that decisions about the HIV 
prevention package to be provided should be balanced 
with the need to ensure that a trial is suﬃ   ciently powered 
to generate an unambiguous result [22].
Inclusion of an increasing number of partially eﬀ  ective 
interventions in the standard prevention package will 
likely decrease HIV incidence and, hence, statistical 
power for evaluating new or potentially more eﬀ  ective 
interventions. Withholding proven interventions, even if 
they are not otherwise available to the local population, 
raises familiar issues of exploitation. Th   is dilemma bears 
many similarities with the challenges faced in deciding 
upon an appropriate and feasible standard for ancillary 
care in biomedical HIV prevention trials, which, as 
previously noted, beneﬁ  tted from empirical research with 
a wide range of stakeholders.
Research would be useful on the long-term eﬀ  ects of 
how we resolve these issues with regard to individual and 
group support for, versus opposition to, taking part in 
trials. Further, informed and comprehensive social analy-
sis of the dilemmas inherent to HIV prevention research 
would potentially move public dialogue about a wide 
range of health inequities forward toward global solu-
tions and contribute to the framing of a global public 
health ethics.
Understanding, measuring and describing complex human 
behaviour
While it is diﬃ   cult to predict anything with certainty, the 
evidence suggests that the eﬀ  ectiveness of some (perhaps 
most) biomedical interventions will vary by gender. 
Circumcision is the obvious example, but there is the 
possibility that antiretrovirals for prevention will show 
complex interactions with biology [45]. Gel-based formu-
lations may be diﬀ  erentially absorbed in the vagina versus 
the anus. Oral pills may show similar diﬀ  erentiation with 
regard to drug availability at the locus of virus entry, or 
they may interact with hormonal contraception. Gender 
norms may inﬂ  uence  eﬃ     cacy if men and women 
experience diﬀ  erential rates of blood exposure through 
the sharing of injection equipment or via iatrogenic 
means. And, of course, there may be social factors that 
lead to gender diﬀ  erences in acceptability, adherence and 
access to interventions that do not vary biologically.
Based on the challenges confronted in providing 
eﬀ  ective contraceptives to women in resource-poor set-
tings, this has serious implications for the successful roll 
out of eﬀ  ective HIV prevention for women [46]. Social 
science research related to gender equity, health policy 
and implementation practices can inform the develop-
ment of solutions to the challenges that are likely to 
emerge. In this regard, important lessons can be learned 
from a review of the social aspects of eﬀ  orts to scale up 
HIV treatment [47].
As placebo-controlled trials become increasingly 
untenable, the classic randomized controlled trial (RCT) 
with longitudinal cohorts and HIV infection as the 
outcome will be severely challenged with regard to 
statistical power [5]. Instead of a trial with 5000 to 10,000 
participants costing $US30 million to $US100 million, a 
non-placebo controlled trial would likely require tens of 
thousands of participants and well over $US100 million. 
By way of example, the RV 144 Phase III HIV vaccine 
trial enrolled about 16,000 participants in Th  ailand, 
lasted about six years, and cost about $US105 million, 
while the MDP 301 Phase III microbicide trial enrolled 
9385 women at multiple sites in Africa and cost $US64 
million [48]. Th   e inclusion of multiple partially eﬀ  ective 
biomedical and behavioural intervention components 
also means that trial designs are becoming more complex, 
which further reduces the power of the classic RCT 
design based on cohorts and incident HIV infections.
Individual behaviour and social context are increasingly 
recognized as important parameters for biomedical 
prevention eﬀ  ectiveness [49,50,51]. Just as we need to 
understand the complexities of HIV at the viral level – 
the genetics, the interaction with human biology at the 
cellular and systemic levels, the molecular susceptibilities 
– we need to understand the complexities of HIV at the 
behavioural and societal levels.
MacQueen Journal of the International AIDS Society 2011, 14(Suppl 2):S3 
http://www.jiasociety.org/content/14/S2/S3
Page 6 of 8Th  e development and testing of combination preven-
tion and multidisciplinary prevention packages stands to 
beneﬁ   t from increased social science leadership. For 
example, the combination of biomedical interventions, 
such as tenofovir gel and male circumcision, with social 
interventions to address gender dynamics and structural 
interventions to address economic drivers oﬀ  er  the 
potential to intervene on the epidemic from multiple 
levels. Th   e design and evaluation of such comprehensive 
packages will not be easy. But one thing we can learn 
from the experience of biomedical HIV prevention is the 
value of perseverance.
Reframing the social
HIV epitomizes the notion of disease as social ecology, 
the absolute necessity of understanding context in order 
to eﬀ  ectively prevent on-going disease transmission. As a 
sexually transmitted disease, HIV is tightly embedded 
with not only individual behaviour, but also with 
behaviours that are at the root of the structuring of 
human society, including gender, marriage, family, house-
hold, kinship, economics and religion. HIV infection is 
complexly related to HIV exposure; similarly, HIV 
infectiousness is complexly determined by the interaction 
of the virus with the human immune system. HIV trans-
mission is not simply an event but a dynamic, evolving 
process that sends its roots into our complex human 
systems over the course of years. As a chronic treated 
condition, those years become decades. HIV is now 
rooted in the social ecology of thousands of communities 
and it has demonstrated its capacity to propagate through 
human generations.
Th   e challenge in reframing the social as a researchable 
and veriﬁ  able component of HIV biomedical prevention 
is to avoid the trap of oversimpliﬁ  cation.  Th  e pre-
dominant biomedical model for identifying eﬀ  ective HIV 
prevention strategies persists in modelling transmission 
as an individual-level event and is built on assumptions 
of simple linear causality and the independence of eﬀ  ects. 
Rather than stripping social analysis of its complexity in 
order to force it into an increasingly limited RCT model, 
we need to bring the social science tools developed for 
studying relationships, interdependence and dynamic 
complexity together with the biomedical tools for 
studying prevention eﬀ  ectiveness. Th  e end result needs 
to be a new way of thinking and of doing research, one 
that integrates social science as a legitimate way of 
framing problems, designing research to address them, 
interpreting ﬁ  ndings and translating research into action.
Conclusions
As social scientists, we need to move beyond a critical 
framing of the social in opposition to the biomedical. We 
need to ask how the dynamics of social change can be 
combined with our increasing understanding of the 
biomedical dynamics of HIV transmission to create, 
evaluate and implement highly eﬀ  ective HIV interven-
tions. We need the opportunity to work with the com-
plexities of social systems with the same degree of nuance 
and rigour that biomedical researchers work with the 
complexities of genetic systems, immune systems and 
population-level transmission dynamics. Our under-
stand  ing of each of these systems includes attention to 
the idiosyncratic as well as the generalizable, the random 
along with the patterned, the mutable together with the 
stable. All have much to oﬀ   er in this endeavour, and 
much to learn.
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